alexa Evaluation of Sanazole Cytotoxicity in Human Drug-Sensitive and MDR Uterine Sarcoma Cells | OMICS International
ISSN : 2153-2435
Pharmaceutica Analytica Acta
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Evaluation of Sanazole Cytotoxicity in Human Drug-Sensitive and MDR Uterine Sarcoma Cells

Mariame A Hassan1,2, Yukihiro Furusawa3, Seisukei Okazawa1,4, Kazuyuki Tobe4 and Takashi Kondo1*

1Department of Radiological Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani 2630, Toyama 930-0194, Japan

2Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr Al-Aini str., Cairo 11562, Egypt

3Laboratory for Mucosal Barriology, International R&D Center for Mucosal Vaccination, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639 Japan

4Department of Internal Medicine, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani 2630, Toyama 930-0194, Japan

*Corresponding Author:
Takashi Kondo
Department of Radiological Sciences
Graduate School of Medicine and Pharmaceutical Sciences
University of Toyama, Sugitani 2630, Toyama 930-0194, Japan
Tel: +81-(0)76-434-7265
Fax: +81-(0)76-434-5190
E-mail: [email protected]

Received date: October 16, 2013; Accepted date: November 27, 2013; Published date: November 29, 2013

Citation: Hassan MA, Furusawa Y, Okazawa S, Tobe K, Kondo T (2013) Evaluation of Sanazole Cytotoxicity in Human Drug-Sensitive and MDR Uterine Sarcoma Cells. Pharmaceut Anal Acta 4:275. doi: 10.4172/2153-2435.1000275

Copyright: © 2013 Hassan MA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Pharmaceutica Analytica Acta

Abstract

Chemotherapy is one of the principle modes of cancer treatment. However, cells adapt to repeated chemotherapeutic exposures in several ways resulting in multidrug resistance (MDR). Therefore, it is mandatory to search for effective alternatives that are refractory to resistant mechanisms. In this study, we investigated the cytotoxicity of sanazole, a nitrotriazole derivative known for its hypoxic radio-sensitization, against a human MDR cell line highly expressing P-glycoprotein that functions as an efflux pump to lipophilic drugs. The results showed that MDR cells exhibited initial sensitivity to the drug compared to the parent sensitive cells. Sanazole action was independent of the degree of resistance and P-glycoprotein expression. Prolonged exposures (48 h) to the drug affected both cell phenotypes viability to a similar extent. However, cell cycle analysis revealed that the underlying pathways differed between cells with respect to their p53 status. For instance, cell cycle was halted in G1- and S-phase in parent and MDR cells, respectively. The (apoptotic) DNA fragmentation in MDR cells was dose-dependently higher compared to the parent cells. Sanazole treatment decreased polyploidy in a dose-dependent manner in MDR cells. The present study provides evidence on the possible potential of sanazole multidrug resistant cancer cells.

 

Keywords

Cytotoxicity; Multidrug resistance; Sanazole; P-glycoprotein; p53

Introduction

“Is resistance Useless?” A question that has been raised by Hall et al. [1] upon reviewing the concept of collateral sensitivity [1]. In that review, the authors mentioned that the development of multidrug resistance in unlikely to be avoidable during cancer treatment. In response to this clinical fact, researchers have been devoted to identify and understand the mechanisms of resistance. Meanwhile, most of the trodden roads to ameliorate this phenomenon have led to what is called the “face-to-face combat” in which the primary aim is to interfere with the pathways inducing resistance. For instance, multidrug resistance has been shown to be mediated primarily by the reduction of intracellular accumulation of chemotherapeutics. This reduction is achieved usually through the expression of transmembrane proteins (adenosine triphosphate (ATP) – binding cassette (ABC) transporters) that function as efflux pumps in a non-specific manner and can thus extrude a wide range of structurally unrelated lipophilic compounds out of the cells against their concentration gradients. Over the last decades, trials have been made to overcome the action of these proteins through the development of inhibitors [2], membrane modification [3-5], dosage form manipulation [6,7], etc. Recently, genetic and transcriptional targeting of biomolecules imparting resistance has been an active area of research despite the difficulties encountered in achieving efficient uptake and reasonable cost [8]. This approach proved feeble and unsatisfactory probably because cells hardly employ one mechanism for resistance. However, another alternative to eradicate resistant cancer cells is to approach them at other sites or to employ their exact adaptive resistive mechanisms as a weapon against them using different drugs.

Here, we present sanazole as a candidate drug to investigate its efficacy against multidrug resistant as well as sensitive cells. Sanazole (AK-2123;N-(2-methoxyethyl)-2-(3-nitro-1,2,4-triazol-1-yl) acetamide) has long been known as a promising hypoxic radiosensitizer since it was synthesized and tested in 1986 [9]. Compared to other hypoxic radiosensitizers, sanazole as a nitrotriazole derivative (Figure 1), has lower general toxicity, higher radiosensitizing effect [10-12] and, moreover, possesses a cytostatic and antimetastatic properties of its own [13,14]. In fact, sanazole can be considered as a bioreductive drug which is reduced inside the cell to give its active metabolites and/ or nitroradicals. Those products can react with essential biomolecules as such or aid in elevating the intracellular oxidative stress resulting in cell death. Though the exact active products are not known, yet, the activation process has been attributed to xanthine oxidase and NADPH/cytochrome P450 reductase [15]. As implied, sanazole effect is attributed to its ability to mimic oxygen in being an electron affinic compound stably accommodating a one-electron, thus its efficacy might be more acknowledged in the absence of oxygen (hypoxic conditions), however, we have previously shown that it can be useful under normoxic conditions [16-18].

pharmaceutica-analytica-acta-structure-Sanazole

Figure 1: The structure of Sanazole (AK-2123): A nitrotriazole derivative frist known for being a hypoxic radiosensitizer. Chemical name: N-(2-methoxyethyl)- 2-(3-nitro-1,2,4-triazol-1-yl) acetamide).

This work comes as fourth in a row demonstrating the potential of sanazole under normoxic conditions and, as far as we know, the first to investigate sanazole effect in an in vitro model of human multidrug resistant cells highly expressing P-glycoprotein (p-gp, the oldest known member of ABC efflux proteins) using clinically relevant doses.

Materials and Methods

Cell lines

Human uterine sarcoma (MES-SA cells) [19] and its multidrug resistant phenotype (MES-SA/DX5) [20] were obtained from American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were generally maintained in complete McCoy’s 5A medium (Gibco BRL, Grand Island, NY, USA) containing 10% fetal bovine serum and 1% antibiotic mixture. A non-enzymatic cell dissociation solution (Sigma- Aldrich, St. Louis, MO, USA) was used for detaching the cell monolayer during splitting and cell culture. MES-SA/DX5 was treated with 500 nM for 1 h once every 8 passages to maintain their Dox resistance [21]. For this study, MES-SA/DX5 cells were plated at a density of 1×103 cells/ml in 10-cm dishes and maintained in complete medium containing 0.5 μM doxorubicin for 2 weeks to select cells with higher levels of resistance. Selected colonies were individually dissociated using 5 mm stainless steel cloning cylinder sealed with sterile high-vacuum grease and the resulting cell suspensions were further cultured in a 24-well plate. The medium was replaced every 48 h, and when confluent, the cells were collected and placed in 6-well plates. Ten colonies were separated and stocked. In our experiments, only one clone (clone V, referred to in the text as MES-SA/DX5v) was used after confirming resistance and P-gp expression.

Drugs

Sanazole was kindly provided as a gift by Emeritus Prof. Tsutomu Kagiya, Kyoto University, Japan. Doxorubicin HCl (Dox) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Both sanazole and Dox were dissolved in sterile phosphate buffered saline (PBS). The final stock solution of San was 100 mM whereas that of Dox was 10 μM. Aliquots of the stock solution were kept at −20°C until use.

Cytotoxicity assay

Twenty-four hours before experiments, the cells were plated in a 96- well plate at a density of 8000 cells/well in fresh complete medium. Cells were then allowed to incubate with different concentrations of sanazole and/or Dox. Following the designated incubation period for each experiment (24 or 48 h), 10 μl of the tetrazolium salt (Cell Counting Kit-8 (CCK-8); Dojindo Molecular Technologies, Inc., Rockville, MA, USA) were added to each well and incubated for 4 h before the color density of the soluble formazan dye product was measured at 450 nm. Each assay was performed in duplicates and McCoy’s 5A medium was used as a blank control. Untreated controls were taken as 100% viability.

P-glycoprotein detection

MES-SA, MES-SA/DX5 and MES-SA/DX5v cells were collected and fixed with 4% freshly prepared paraformaldehyde (PFA)/PBS for 30 min at room temperature. After thorough washings, fixed cells were incubated for 30 min at room temperature with 2% bovine serum albumin (BSA)/PBS to block non-specific binding. Cells were then reacted sequentially with the primary monoclonal antibody (mAb) Anti-Pgp/MDR1 mAb (Clone: MRK16) (Kyowa Medex, Tokyo, Japan) and the secondary antibody Alexa Fluor 488 anti-mouse F (ab’) IgG (Cell Signaling Technology, Beverly, MA, USA) for at least 1 h for each antibody before they were analyzed flow cytometrically (Epics XL, Beckman Coulter, Miami, FL, USA).

Cell cycle analysis

Control and treated cells were quantitatively collected and fixed with 70% pre-chilled ethanol for at least 2 h. Fixed cells were resuspended in PBS containing RNAase (Nacalai Tesque, Kyoto, Japan) at a final concentration of 0.25 mg/ml/1×106 cells for 30 min at room temperature. Cell pellets were finally suspended in 50 μg/ml propidium iodide (PI)/PBS staining solution and incubated in dark at 4°C for 20 min before flow cytometric analysis.

Assessment of intracellular reactive oxygen species (ROS)

Intracellular reactive oxygen species (ROS) were assessed at 6 and 24 h after treatment of cells with different doses of sanazole. The analysis was performed with flow cytometry using hydroethidine (HE) and dichlorofluorescein diacetate (DCFH-DA) (Molecular Probes, Eugene, OR, USA) [18,22]. Cells were collected, washed twice with PBS, and resuspended in 2 μM HE or 5 μM DCFH-DA in PBS. The samples were incubated at 37°C in the dark before flow cytometric analysis.

Assessment of H2AX phosphorylation

Cells were treated with different doses of sanazole for 24 h and then collected quantitatively and fixed with 70% cold methanol overnight. Cells were permealized for 30 min at room temperature with 0.05% Tween/PBS containing 2% BSA to block non-specific binding. Cells were then reacted sequentially with the primary monoclonal antibody (mAb) anti-phospho-H2AX S139 (γH2AX) (Upstate Biotechnology, Lake Placid, NY, USA) and the secondary antibody Alexa Fluor 488 anti-mouse F (ab’) IgG (Cell Signaling Technology, Beverly, MA, USA) for at least 1 h for each antibody before they were analysed flow cytometrically [23,24]. Cells treated with Dox (1 μM) for 24 h were used as a positive control.

Western blot analysis

Control and treated cells were suspended in lysis buffer (50 mM NaCl, 1% Nonidet P-40 and 50 mM Tris-HCl, pH 8.0) containing protease inhibitors cocktail (Nacalai Tesque, Kyoto, Japan). SDSpolyacrylamide gel electrophoresis and Western blot analysis were carried out as described elsewhere [23]. The primary antibodies used were as follows: a rabbit polyclonal anti-p53 antibody (Cell Signaling Technology, Beverly, MA, USA); a mouse monoclonal anti-p21WAF1/ CIP1 antibody (MBL, Nagoya, Japan); and a mouse monoclonal antiglyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (Organon Teknika, Durham, NC, USA). Immunoreactive proteins were visualized using enhanced chemiluminescence (ECL) detection system on a luminescent image analyser (LAS-4000, Fujifilm, Tokyo, Japan).

Statistical analysis

Experiments were performed in independent triplicates. All results are displayed as mean ± standard error of the mean (SEM). Tests of significance were performed using unpaired t-student test (twotailed) with p<0.05 considered to be statistically significant. Correlation coefficients (r2) and their p-values (cut off % = 0.05) among data sets were calculated using GraphPad Prism 5 (GraphPad Software; San Diego, CA).

Results and Discussion

MES-SA/DX5 cells are the resistant counterpart of the human uterine sarcoma cell line MES-SA selected by continuous exposure to escalating doses of Dox [20]. The resistance in these cells has been mainly correlated to the overexpression of P-gp [25-28]. However, our previous work revealed that this cell line displays a weak phenotype of resistance with only one-third of the cells expressing P-gp, the thing that requires a booster Dox treatment of 500 nM for 1 h every 8 splits [24]. For this study, MES-SA/DX5 cells were further selected and continuously maintained under nanomolar concentrations of Dox to maximize and maintain resistance. To confirm the efficiency of this procedure, one of the selected clones (clone V; hence MESSA/ DX5v), MES-SA/DX5, and MES-SA cells were treated with serial concentrations of Dox for 24 h and their survival was assessed. As shown in Figure 2A, MES-SA/DX5v showed higher resistance to Dox compared to the original MES-SA/DX5 cells. The higher resistance encountered was associated with almost complete expression of P-gp (Figure 2B). A similar assessment to sanazole cytotoxicity was carried out by exposing the three phenotypes to sanazole for 24 h. The range of sanazole concentrations used has its median concentration (5 mM) relevant to the dose administered intravenously to human subjects in clinical studies [12,29]. We noticed that both MES-SA/DX5 and MESSA/ DX5v responded similarly indicating that sanazole effect might not rely on the extent of P-gp expression (Figure 2C). However, since MESSA/ DX5v was continuously maintained in subcultures under 250 nM Dox where Dox was only withdrawn before drug addition, MES-SA/ DX5v cells were used in subsequent experiments to ensure constant level of resistance through the study and to help evaluate the efficacy of sanazole treatment under Dox, a condition closer to in vivo.

pharmaceutica-analytica-acta-uterine-sarcoma-cell

Figure 2: Differential responses of uterine sarcoma cell variants MES-SA, MES-SA/DX5, and MES-SA/DX5v. Cell survival following 24 h incubation with a serial of Dox concentrations (A). Expression of P-gp under culture conditions (B). Cell survival following 24 h incubation with a serial of sanazole concentrations (C). Sanazole cytotoxicity is independent from P-gp expression in MES-SA/DX5 and MES-SA/X5v cells. Data presented is the average ± SEM of at least 3 independent replicates.

The inspection of the survival data at 24 h shows clearly that at higher doses above 5 mM, the survival of the resistant cells was significantly lower than the parental cells. Taking into consideration a) The difference in doubling time of both cell variants (22-24 h for MESSA and 30 h for MES-SA/DX5), and b) The relatively long elimination half-life of sanazole (T½β ≈ 35 h [29]), cell survival was also evaluated after 48 h treatment. Interestingly, both cell variants displayed similar survival percentages at all sanazole doses after 48 h exposure (Figure 3). Sanazole concentrations required to kill 50% of cell population (EC50) based on 24 and 48 h survival data were 6.5 and 1.9 mM for MES-SA cells, and 3.3 and 1.8 mM for MES-SA/DX5 cells, respectively. These results collectively reflect the efficiency of the drug as an anticancer agent regardless of drug resistance under our study conditions.

pharmaceutica-analytica-acta-Dose-response-curves

Figure 3: Dose response curves of sanazole cytotoxicity. Cell survival was assessed after 24 or 48 h treatment with a serial concentrations of sanazole in MES-SA and MES-SA/DX5v cells. Data presented is the average ± SEM of at least 3 independent replicates.

Despite the similar survival patterns, the underlying events showed significant differences between both cell phenotypes. For instance, in cell cycle analyses of treated cells, MES-SA and MES-SA/DX5v showed significant arrest in different cell cycle phases, namely, G1- and S-phases, respectively (Figures 4A-D). Following a 48 h - incubation period with the drug, the cell cycle retained the respective arrest pattern even at lower doses of the drug (Figures 4B and 4D). Mitsuhashi et al. [30] has previously reported a similar G1 arrest in rodent cells after exposure to sanazole for 24 h [30]. The similar results obtained in our study suggest that the underlying mechanism might be conserved among vertebrates. MES-SA cells are reported to possess a wild type p53 [31] which is activated upon sensing DNA damage and consequently upregulates the cyclin dependent kinase inhibitor (CKI) p21 inducing a G1 arrest [32]. This scenario was confirmed in western blot results shown in Figure 4E. MES-SA/DX5v cells seemed to have an impaired p53 - functionality and thus p21, a typical downstream target of p53, could not be activated resulting in an initial escape from a similar G1 arrest. This could be in addition to the reported invariability in Annexin A7 expression in response to Dox treatment which allows MES-SA/ DX5 cells to escape G1 arrest [28]. However, the cells were instead trapped in the S-phase possibly upon the activation of the intra-S-phase checkpoint which is beyond the control of p53 and p21 [32-34]. On the other hand, the inspection of the subG1 fraction (supposedly apoptotic cells with fragmented DNA) showed that it increased proportionally in both cell lines. The maximum subG1 fraction observed was >2.5-fold higher in MES-SA/DX5v cells compared to MES-SA cells. This ratio was conserved after 48 h - incubation period with half of the sanazole dose. Further statistical analysis of the cell cycle data revealed a sort of negative linear correlation between cell polyploidy and apoptosis induction. The correlation was also stronger in MES-SA/DX5v cells as compared to MES-SA cells (correlation coefficients (r2) were -0.46 (p=0.54) and -0.94 (p=0.06) at 24 h and -0.14 (p=0.83) and -0.85 (p=0.07) at 48 h for MES-SA and MES-SA/DX5v, respectively). This decrease may indicate that the resistant cells were encountering massive DNA damage that could not be repaired or overcome, the thing that culminated in possibly cell death as manifested by the higher percentage of cells in SubG1 fraction. To test this hypothesis, we analysed the presence and the extent of phosphorylated H2AX foci (γH2AX) flow cytometrically in comparison to Dox (1 μM). Figure 5 shows that MES-SA/DX5v cells had higher mean fluorescence intensities at all sanazole doses in contrast to Dox treatment which exerts its maximum cell killing effect preferentially in MES-SA cells at 1 μM dose [24]. It is worth mentioning that the evaluation of γH2AX after 24 h of treatment might be interpreted as being partially a consequence of apoptosis as well as a consequence of DNA damage induced by sanazole [35]. The correlation between subG1 fraction and the extent of γH2Ax yielded higher coefficient with MES-SA cells (0.951, p=0.05) compared to MES-SA/DX5v cells (0.83, p=0.174). Thus, the data as such supports that the DNA damage observed in MES-SA/DX5v cells might be a causative rather than a consequence.

pharmaceutica-analytica-acta-Changes-cell-cycle

Figure 4: Changes in cell cycle and the expression of some relevant proteins by sanazole treatment. Cell cycle analyses in treated MES-SA cells showing G1 arrest after 24 h treatment with sanazole at 2, 5 and 10 mM (A), and after 48 h treatment with sanazole at 0.5, 1, 2 and 5 mM (B). In treated MES-SA/DX5v cells, S-phase arrest was observed after 24 h treatment with sanazole at 2, 5 and 10 mM (C), and after 48 h treatment with sanazole at 0.5, 1, 2 and 5 mM (D). Asterisks (*) indicate statistical significance (p<0.05). Western blot analysis shows the expression of p53 and p21 proteins following a 24 h-incubation period with different doses of sanazole (E).

pharmaceutica-analytica-acta-H2AX-phosphorylation

Figure 5: H2AX phosphorylation. The mean fluorescence intensity (MFI) of labeled γH2AX in control and treated MES-SA and MES=SA/DX5v cells was detected flow cytometrically 24 h after treatment. Dox (1 μM) was used as a positive control. For quantification of data, the mean fluorescence intensity index (MFII) was calculated as follows: (MFI of treated cells – MFI of control cells) / MFI of control.

The assessment of intracellular ROS elevation showed that ROS were involved early in the cellular response to sanazole. Figure 6 shows that sanazole treatment primarily induced superoxide anion (O2-.) elevation whereas the peroxides production was generally lower in comparison in both cell variants. This differential elevation in intracellular ROS might be dependent on cell type as shown in previous studies [17,18]. Also, the data shows that the resistant cells always possessed lower intracellular ROS levels, especially at higher doses, which might be due to the so-called adaptive antioxidant response [22].

pharmaceutica-analytica-acta-Intracellular-ROS-elevation

Figure 6: Intracellular ROS elevation by sanazole treatment. Sanazole was added at different concentrations to cultured MES-SA and MES-SA/DX5v. Samples were collected at 6 h (A&C) and 24 h (B&D). Control and treated samples were analysed flow cytometrically for superoxide anion (O2-.) elevation using hydroethidine (HE) (A&B), and for peroxides elevation using dichlorofluorescein acetate (DCFH-DA) (C&D).

The compilation of the results presented here suggests that sanazole is a potent cytostatic agent that is not a substrate to P-pg and its mechanism of action is apparently independent from multidrug resistance displayed by the cells under study. Sanazole also may possibly have a different target site(s) compared to Dox. If this holds true, we would expect an additive effect if sanazole is given in combination with Dox. To prove this assumption, we assessed cell survival after adding Dox and sanazole simultaneously to MES-SA or MES-SA/DX5v cells. Different doses of Dox were selected to represent the reported three cell death modes induced by Dox [24,36], namely 0.1, 1 and 10 μM, whereas sanazole was added at a concentration of 2 mM as an intermediate dose in the range employed in this study and a dose that corresponds to clinical concentrations. A 24 h-incubation period with both drugs showed an additive decrease in cell survival under all treatment conditions (Figure 7). Interestingly, this additive response was observed in both cell variants confirming that the cytotoxicity of sanazole is mediated through different pathways than those underlying the cytotoxicity of Dox and thus independently from resistance.

pharmaceutica-analytica-acta-sanazole-doxorubicin

Figure 7: Simultaneous combination of sanazole and doxorubicin. Cell survival of MES-SA and MES-SA/DX5v cells treated with 2 mM of sanazole and 0.1, 1 or 10 μM of doxorubicin simultaneously for 24 h.

In conclusion, this study confirms the antitumor and the cytostatic activity of sanazole under aerobic conditions in human cells. It also highlights its efficiency against MDR cells where it could exert its action independently from P-gp overexpression and probably from other mechanisms for resistance. Although the initial sensitivity of MES-SA/DX5v cells compared to its parental counterpart after 24 h treatment can be justified by the doubling time differences, it might be possible that the altered proteomics of the resistant cells facilitate a prompt bioactivation of the drug. Resistant cells have been reported to undergo an adaptive antioxidant mechanism through the modulation of the expression of certain enzymes so that they can acquire protection against oxidative stress induced by pro-oxidant chemotherapeutics such as Dox [22]. Available data shows that this scenario occurs in MESSA/ DX5 cells ([28], unpublished data) during acquiring resistance. An enzyme of interest is the xanthine oxidoreductase enzyme encoded in human by the gene HDX. This particular enzyme has been reported to be involved in the bioactivation of sanazole to exert its antitumor and radiosensitizing effects [15].

Although the role of sanazole in reversing MDR has been previously reported, this study aspires its novelty in the utilization of human cells, in contrast to the previous studies which withdrew their conclusions from rodent cells [37,38]. Also, this study provides an insight of some of the molecular events involved and opens the way for considering other bioreductive drugs that are refractory to P-gp efflux as possible chemotherapeutics against multidrug resistant cancer cells.

Acknowledgement

Financial support for this study was provided by a Grant-in-Aid for Scientific Research (B) (22390229), Japan Society for the Promotion of Science (to TK), and by research grant from International Association of Sensitization for Cancer Treatment (IASCT) (to MA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • 7th International Conference on Phamaceutical Auditing
    June 08-09, 2018 Baltimore, USA
  • 4th International Conference on Drug Discovery, Designing and Development
    June 27-28, 2018 Vancouver, Canada
  • 18th World Pharma Congress
    October 18-19, 2018 Warsaw, Poland

Article Usage

  • Total views: 11802
  • [From(publication date):
    November-2013 - Apr 25, 2018]
  • Breakdown by view type
  • HTML page views : 8029
  • PDF downloads : 3773
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version